The big gene enclosure door informant issued suicide note that it will commit suicide Huada alarm.

category:Society click:562
 The big gene enclosure door informant issued suicide note that it will commit suicide Huada alarm.


In response to this matter, Huada said it had called the police. In response, Huada has been trying to protect the legitimate rights and commercial reputation of enterprises through legitimate legal means. We have never, and we do not want any party to treat this matter in an extreme way.

Report door again storm

Wang Deming published a suicide note on the Internet that he from the National Gene Bank Cell Center Jiangsu Operating Center Director helpers, suddenly turned into a wild breed of Qidan, Huada Gene heroes collective attack impersonation.

But before this, Wang Deming said that Nanjing Changjian and Huada had talked about the cooperation for half a year. In the cooperation, Shenzhen Huada Institute of Gene Research put forward the technical proposal, and Nanjing Changjian was responsible for market operation and market development. Wang Deming firmly believed that Jiangsu Operating Center was actually established and recognized by Huada at that time. The two sides formally signed the contract on March 29, 2016. At the same time, it also provides relevant commercial websites to report on this matter and related mail to corroborate. But in an interview with the media including Nandu on July 10, Xu Xun, CEO of Huada Group, said that Jiangsu Operating Center had encountered various practical difficulties in the preparatory process and had not really been established.

In addition, Wang Deming said in the posthumous letter, according to the contract, we deserved a profit of 17.49 million-77.41 million, I did not want the highest or even the average, I only claimed the lowest amount of 17.49 million, and promised not to mention the word Huada or even no longer contact with the gene industry in my lifetime.

Regarding the previous cooperation between Nanjing Changjian and Huada Gene, Wang Deming said that on January 16 this year he received an express letter from Huada Gene, which stated that Huada Gene would terminate its cooperation with Nanjing Changjian Yujia. It is very puzzled about this. It has made a clear statement that unilaterally cancelling cooperation with Chinese genes. Since then, he has had 5 months of communication with many Chinese genes, and the two sides failed to reach an agreement.

As for the termination of the contract, Huada said that in January this year, because Changjian Nanjing only completed 17 cell storage samples, accounting for 5.7% of the annual target of 300 cases, is a fundamental breach of contract, the research institute sent a termination notice to formally terminate the National Gene Bank Technical Service Contract.

On Aug. 1, Wei Wei, assistant president of Huada Group, said that the fact of the agreement was that Changjian had breached the contract and Huada had only exercised its statutory right to rescind it. At present, Huada has already done so in Shenzhen and Nanjing on the infringement of Wang Deming and Changjians reputation (infringement of reputation and unfair competition). The Xuanwu Branch of Nanjing Public Security Bureau has also issued a notice to cancel the two official seals of National Gene Bank Cell Center Jiangsu Operating Center and National Gene Bank Cell Center Jiangsu Operating Center Financial Seal engraved by Nanjing Jianyoujia Health Management Co., Ltd.

Meanwhile, Huada said again today that the National Gene Bank Technology Service Contract signed by Shenzhen Huada Gene Research Institute (now renamed as Shenzhen Huada Life Science Research Institute) and Nanjing Changjianyou Jia Health Management Co., Ltd. (Nanjing Changjian) was due to Nanjing. Chang Jian had a fundamental breach of contract, and the Institute formally terminated it in January 2018. Since January 2018, Nanjing Changjian has never brought a lawsuit to any judicial organ for arbitration of the dissolution itself.

Cases of mutual prosecution were postponed.

Since the reporting door fermentation, Nanjing Changjian and Huada have launched a tug-of-war for several months, the two sides also sued each other for related matters. Nandu reporter learned that the case of Changjian v. Huada gene infringement of the right of reputation was originally scheduled to open in the afternoon of July 18, when Wang Deming said that the case had been confirmed to be postponed.

Earlier this morning, Huadas response also said that Shenzhen Huada Gene Technology Co., Ltd. (hereinafter referred to as Huada Group) had filed a lawsuit against Changjian Nanjing and Wang Deming Wang in Shenzhen Yantian District Peoples Court for infringement of the right of reputation, and Shenzhen Huada Academy of Life Sciences in Nanjing Jianye District Peoples Court against Nan. Jing Chang Jians lawsuit against unfair competition has been postponed for two reasons. However, Hua Da group extended the case of Nanjing Changjian and Wang Demings infringement of reputation right until September 17th. Nandu reporters noted that the reporting door incident led to both sides badly hurt. By the end of September 14, Huada Gene (300676.sz) was reported at 71.81 yuan, with a market value of 28.7 billion yuan, down sharply from its peak value of 100 billion yuan. Earlier, its semi-annual report showed revenue of 1.141 billion yuan in the first half of the year, an increase of 28.44%; net profit of 208 million yuan belonging to shareholders of listed companies, an increase of 8.73%; net profit of 168 million yuan, excluding recurring gains and losses, belonging to shareholders of listed companies. Source: Southern Metropolis Daily editor in charge: Zhao Yaping _NN9005

Earlier this morning, Huadas response also said that Shenzhen Huada Gene Technology Co., Ltd. (hereinafter referred to as Huada Group) had filed a lawsuit against Changjian Nanjing and Wang Deming Wang in Shenzhen Yantian District Peoples Court for infringement of the right of reputation, and Shenzhen Huada Academy of Life Sciences in Nanjing Jianye District Peoples Court against Nan. Jing Chang Jians lawsuit against unfair competition has been postponed for two reasons. However, Hua Da group extended the case of Nanjing Changjian and Wang Demings infringement of reputation right until September 17th.

Nandu reporters noted that the reporting door incident led to both sides badly hurt. By the end of September 14, Huada Gene (300676.sz) was reported at 71.81 yuan, with a market value of 28.7 billion yuan, down sharply from its peak value of 100 billion yuan. Earlier, its semi-annual report showed revenue of 1.141 billion yuan in the first half of the year, an increase of 28.44%; net profit of 208 million yuan belonging to shareholders of listed companies, an increase of 8.73%; net profit of 168 million yuan, excluding recurring gains and losses, belonging to shareholders of listed companies.